Thomas William Barnhill M.A.

Recommended Articles

• What Is a Prefrontal Lobotomy?

  Lobotomy is a neurosurgical procedure invented in 1935 by a Portuguese neurologist named Moniz. Moniz won the Nobel Prize in 1949 for his achievement. It was believed that lobotomy was successful in the treatment of various psychological diseases like depression, bipolar disorders, mania,...

• Can Berries Prevent Memory Loss?

  Recent studies show that eating berries may help to prevent age-related memory loss and keep memory sharp during old age. The researchers claim there is strong evidence that berries can improve the functioning of the brain and prevent memory loss. Researcher Marshall Miller, of the USDA-ARS Human...

• Childhood Crohn’s Diagnosis Linked with Cancer Risk, Study Finds

  Inflammatory bowel disease most often affects young adults. However, children can also be diagnosed too. When inflammatory bowel disease affects a child, it causes painful gastrointestinal symptoms that are especially difficult for kids to bear.It's hard for kids to understand what's happening to...

• One Step Closer to a Cure: New Developments in Parkinson’s Research

  Parkinson's disease is a neurodegenerative disease that affects a lot of people worldwide with an estimated figure of about 1 million in the United States alone, according to the National Parkinson’s Foundation. Despite the sheer amount of support available for patients as seen in the dozens of...

• Research Gives Muscular Dystrophy Patients New Hope

  Regardless of the person’s age, sex, or where they are from, being told that they have a progressive disease like muscular dystrophy is devastating.  It means learning to live with a disease that makes muscles waste away.  For many, one of the coping mechanisms they turn to is to learn as much...

• FDA Approves Orkambi to Treat Young Children with Cystic Fibrosis

  Orkambi is an oral drug developed by Vertex Pharmaceuticals and approved by the United States Food and Drug Administration (FDA) for the treatment of cystic fibrosis (CF) in certain patient groups. It is the second drug to be approved for use in patients with CF, after Kalydeco. ...